Research location
Alicante
Spain
Research activity in Alicante
SpainCureCurrent currently publishes aggregate city-level research activity for this location: 432 trials and 456 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Alicante
432 linked trials · page 1 of 9A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)NCT07465757 · 2026-09-17 · 1 site observation
RECRUITING
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCNCT07586202 · 2026-07-28 · 1 site observation
RECRUITING
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsNCT07106632 · 2026-06-26 · 1 site observation
RECRUITING
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedNCT07650916 · 2026-06-25 · 1 site observation
RECRUITING
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2NCT07203053 · 2026-04-15 · 1 site observation
RECRUITING
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerNCT07195227 · 2026-03-24 · 1 site observation
RECRUITING
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementNCT07371585 · 2026-02-18 · 1 site observation
RECRUITING
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)NCT07202546 · 2026-02-11 · 1 site observation
RECRUITING
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior ChemotherapyNCT06931717 · 2026-01-12 · 1 site observation
RECRUITING
NOPE37: Angiogenic Factors for Managing Term PreeclampsiaNCT07193680 · 2025-12-04 · 1 site observation
RECRUITING
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALSNCT07142291 · 2025-11-25 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisNCT07225504 · 2025-11-11 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeNCT07284121 · 2025-07-15 · 2 site observations
RECRUITING
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeNCT06486883 · 2025-06-30 · 1 site observation
RECRUITING
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisNCT06315010 · 2025-06-27 · 1 site observation
RECRUITING
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or DfNCT07348302 · 2025-04-02 · 1 site observation
RECRUITING
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06 · 1 site observation
RECRUITING
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCNCT06078384 · 2024-12-27 · 1 site observation
RECRUITING
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.NCT06382948 · 2024-12-05 · 2 site observations
RECRUITING
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerNCT06369285 · 2024-11-19 · 1 site observation
RECRUITING
Integrated Approach in Frail Older People with Atrial FibrillationNCT06775028 · 2024-04-11 · 1 site observation
RECRUITING
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsNCT06357533 · 2024-04-11 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation
RECRUITING
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · 2023-12-15 · 1 site observation
RECRUITING
DESTINY Breast Respond HER2-(Ultra)Low EuropeNCT05945732 · 2023-10-24 · 1 site observation
RECRUITING
Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)NCT06055504 · 2023-09-06 · 1 site observation
RECRUITING
OSIREAL - Osimertinib RWE on EGFRm NSCLC in SpainNCT06068049 · 2023-07-28 · 1 site observation
RECRUITING
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)NCT05427370 · 2023-06-22 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 · 2022-12-16 · 1 site observation
RECRUITING
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT05498428 · 2022-11-11 · 1 site observation
RECRUITING
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerNCT05061550 · 2022-04-14 · 1 site observation
RECRUITING
Efficacy and Safety Evaluation for the Treatment of Allergy Against MitesNCT04435990 · 2020-10-06 · 2 site observations
RECRUITING
Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM StudiesNCT03390894 · 2018-01-18 · 4 site observations
RECRUITING
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)NCT02819882 · 2016-08-01 · 1 site observation
RECRUITING
Optimizing the Use of Aspirin for the Prevention of PreeclampsiaNCT07665853 · 2026-07-01 · 1 site observation
NOT_YET_RECRUITING
Cancer Literacy Education and Awareness Resources for Prostate CareNCT07437482 · 2026-03-01 · 1 site observation
NOT_YET_RECRUITING
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)NCT07074886 · 2025-11-13 · 1 site observation
ACTIVE_NOT_RECRUITING
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLCNCT06068153 · 2025-03-01 · 1 site observation
WITHDRAWN
Psychological Factors and Self-Care Behaviors in Spanish Youth With Type 1 Diabetes: Age- and Sex-Based Comparisons and AssociationsNCT07452393 · 2025-02-17 · 1 site observation
COMPLETED
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainNCT06764186 · 2025-01-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)NCT06635824 · 2024-11-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)NCT06516965 · 2024-10-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)NCT06430866 · 2024-09-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerNCT06311721 · 2024-09-09 · 1 site observation
ACTIVE_NOT_RECRUITING
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerNCT06172127 · 2024-07-22 · 2 site observations
ACTIVE_NOT_RECRUITING
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung CancerNCT05718297 · 2024-06-07 · 1 site observation
WITHDRAWN
Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental DopplerNCT05284474 · 2024-06-03 · 1 site observation
NOT_YET_RECRUITING
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationNCT05708235 · 2024-04-01 · 3 site observations
ACTIVE_NOT_RECRUITING
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.